Monday June 4, 7:15 pm Eastern Time
Press Release
Phage Therapeutics Annual General Meeting On September 10, 2001
BOTHELL, Wash.--(BUSINESS WIRE)--June 4, 2001--Phage Therapeutics International Inc. (OTCBB:PTXX - news; the ``Company'') wishes to announce that it has adjourned its annual general meeting to September 10, 2001 at 11 a.m. (the ``AGM'').
The AGM will be held at the Company's headquarters at 19017 120th Avenue NE, Suite 102, Bothell, Washington. The shareholders of record will be re-set and announced closer to the AGM date.
Phage Therapeutics International Inc. is a Florida corporation, doing business in Washington State, formed to develop, manufacture and achieve regulatory approval of bacteriophage pharmaceutical products for the treatment of antibiotic-resistant and other bacterial infections.
Currently, the Company has 13,188,301 shares issued and outstanding.
Phage Therapeutics International Inc.
``Darren Pylot''
Darren Pylot, Chief Financial Officer & Director
The SEC and NASD have not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Forward-looking statements and comments in this press release are made pursuant to safe harbor provisions of the Securities Exchange Act of 1934. Certain statements which describe the Company's intentions, expectations or predictions, are forward-looking and are subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events. Factors which could cause results or events to differ from current expectations include, among other things: the impact of rapid technological and market change; general industry and market conditions and growth rates; international growth and global economic conditions, particularly in emerging markets and including interest rates and currency exchange rate fluctuations; and the impact of consolidations in the technology industry. These risks may further be discussed in periodic reports and registration statements to be filed by the Company from time to time with the Securities and Exchange Commission in the future.
--------------------------------------------------------------------------------
Contact:
Phage Therapeutics International Inc.
Investor Relations
Chris Tomanik, 888/224-4144 |
